ALK and neuroblastoma: The identification of ALK mutations in subsets of neuroblastoma primary tumors and more commonly in relapsed samples (5, 6, 9–11) resulted in trials of ALK inhibitors and development of newer compounds with better efficacy against activating missense mutations.